Met nsclc w/ egfr alk oth ab

Full descriptor

Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement

Details

Code

M1412

Short descriptor

Met nsclc w/ egfr alk oth ab

Code set

HCPCS Level II

Release

July 2026

Status

Active

Added

Jan 1 2025

Nearby codes

Code sets are published in blocks, so neighbours are usually related.